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Methods: We defined a study population within the Psoriasis Longitudinal Assessment and Registry and
measured the incidence of depressive symptoms (Hospital Anxiety and Depression ScaleeDepression
score $8) and adverse events (AEs) of depression within cohorts receiving biologics, conventional
systemic therapies, or phototherapy. Patients were evaluated at approximately 6-month intervals.
Multivariate modeling determined the impact of treatment on risk.
Results: The incidence rates of depressive symptoms were 3.01 per 100 patient-years (PYs) (95%
confidence interval [CI], 2.73-3.32), 5.85 per 100 PYs (95% CI, 4.29-7.97), and 5.70 per 100 PYs (95% CI,
4.58-7.10) for biologics, phototherapy, and conventional therapy, respectively. Compared with
conventional therapy, biologics reduced the risk for depressive symptoms (hazard ratio, 0.76; 95% CI,
0.59-0.98), whereas phototherapy did not (hazard ratio, 1.05; 95% CI, 0.71-1.54). The incidence rates for
AEs of depression were 0.21 per 100 PYs (95% CI, 0.15-0.31) for biologics, 0.55 per 100 PYs (95% CI,
0.21-1.47) for phototherapy, and 0.14 per 100 PYs (95% CI, 0.03-0.55) for conventional therapy; the fact that
there were too few events (37 AEs) precluded modeling.
Limitations: Incomplete capture of depression and confounders in the patients on registry.
Conclusion: Compared with conventional therapy, biologics appear to be associated with a lower
incidence of depressive symptoms among patients with psoriasis. ( J Am Acad Dermatol 2018;78:70-80.)
Key words: biologic therapy; depression; phototherapy; PSOLAR; psoriasis; systemic therapy.
Several studies have documented an increased
risk for depression and suici-
dality among patients with
psoriasis. Cross-sectional
studies with relatively small
sample sizes have noted a
high prevalence of depres-
sion ([60%) and suicidality
([7%) among patients with
psoriasis.1,2 A large cohort
study in the General
Practice Research Database
found an increased risk for
depression, anxiety, and
suicidality among patients
with psoriasis; depression
and suicidality risks were
higher for patients with
severe disease.3 Another
large cohort analysis, using
data from the Nurses’ Health Study, found an
increased risk for depression in women with
psoriasis and psoriatic arthritis.4 A recent
meta-analysis reported similar findings, indicating
that patients with psoriasis were at least 1.5 times
more likely to experience depression than patients
without psoriasis.5
Depressive symptoms, as opposed to
depression, are assessed by the Hospital Anxiety
and Depression ScaleeDepression (HADS-D)
(Table I). Data from clinical trials support a reduction
in depressive symptoms with psoriasis treatment.
In the pivotal clinical trials for adalimumab,
etanercept, ustekinumab, and infliximab, depressive
symptoms were decreased.6-10 However, beyond
clinical trials, there is a
paucity of well-controlled or
real-world data addressing
the effect of systemic therapy
on comorbid depression
and suicidality among pa-
tients with psoriasis. Herein
we report findings on the
prevalence, incidence, and
impact of systemic therapy
on comorbid depression
and depressive symptoms
among patients in Psoriasis
Longitudinal Assessment and
Registry (PSOLAR).11
METHODS
Study design
A full description of
PSOLAR has been reported previously.11,12
Briefly, PSOLAR is a prospective, longitudinal,
disease-based registry designed to collect
safety, efficacy, and health outcomes data from
approximately 12,000 patients with psoriasis in
16 countries who are receiving, or are eligible
to receive, conventional systemic or biologic
therapies. All patients provided written informed
consent before the start of the study, and an
institutional review board or ethics committee
approved the registry protocol at participating
sites. This cohort analysis used data obtained
through August 23, 2015.
CAPSULE SUMMARY
d Patients with psoriasis have an increased
risk for depression/suicidality.
d Biologic agents for psoriasis were
associated with a decreased incidence of
depressive symptoms versus
conventional systemic therapies in the
real-world Psoriasis Longitudinal
Assessment and Registry.
d Further exploration of the relationship
between biologics and depression
among patients with psoriasis is
warranted to optimize treatment
management.
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Objectives
The primary objectives of this analysis were
to calculate the prevalence and incidence
of depression and symptoms suggestive of
depression among PSOLAR patients with
moderate-to-severe psoriasis and to assess the
effect of systemic treatment on the risk for
development of these outcomes. Symptoms
suggestive of depression were evaluated using
the HADS-D (Table I).13 Incidence of depression
was based on reports of adverse events (AEs) of
depression. An additional objective was to
describe suicidality, including completed suicide,
suicide attempt, or suicidal ideation.
Cohorts, exposures, outcomes, and statistical
methods
To study the incidence of depression and
symptoms of depression, the study population
was defined by using the following criteria: no
medical history of depression, a HADS-D score lower
than 8 at baseline, and exposure to only 1 study
therapy (ie, monotherapy). Exposure cohorts
were defined as patients treated with (1) biologics
(etanercept, adalimumab, infliximab, and ustekinu-
mab), (2) phototherapy (including ultraviolet B
and psoralens plus ultraviolet A light), or (3) conven-
tional systemic agents (including methotrexate,
cyclosporine, systemic corticosteroids, fumarates,
mycophenolate mofetil, and oral retinoids).
Exposure started at the date of the first dose of a
cohort-defining therapy on registry (or at enrollment
for those who entered the registry while undergoing
therapy) and ended at the date of the last
cohort-defining therapy dose, the date of switching
to a different therapy, discontinuation from
the registry, data extraction (August 23, 2015), or
death. Outcomes included symptoms suggestive of
depression (HADS-D score $8) and an AE of
depression (according to the Medical Dictionary for
Regulatory Activities [MedDRA], version 17.1,
Standardized MedDRA Queries for Depression
and Suicide/Self-injury). These outcomes were
considered separately, and patients were followed
only until the first occurrence of either outcome.
HADS-D data were to be collected at baseline, every
6 months for the next 18 months, and every
12 months thereafter. AEs were to be collected every
6 months; depression was considered an AE of
special interest and subjected to enhanced reporting
efforts. Suicidality was assessed on the basis of
reporting of terms from the Suicide/Self-injury
Standardized MedDRA Query; individual cases
were classified as completed suicide, suicide
attempt, or suicidal ideation.
Incidence rates (IRs) were calculated for
depressive symptoms (an initial HADS-D score $8)
or AE of depression for each of the 3 cohorts
(combined biologics, phototherapy, or conventional
systemic therapy) and for each individual biologic
agent. Cox proportional hazards regression models
were used to estimate risk on the basis of time to first
outcome for each of the treatment cohorts after
adjustment for a predefined list of potential
confounders as discussed in the Results. Each
covariate was independently tested for association
with each outcome (univariate P value\ .20) and
included in the final model if an association was
confirmed. Hazard ratios (HRs), confidence intervals
(CIs), and P values (based on a Wald x2 test) were
calculated independently for the combined biologics
and phototherapy cohorts versus the conventional
therapy reference cohort. Each biologic was also
separately compared with the conventional therapy
reference cohort. To evaluate their potential
confounding effect, a post hoc analysis excluding
patients with concomitant oral retinoid (acitretin and
etretinate) use from the conventional systemics
cohort was conducted. Missing values for covariates
were imputed (ie, means for continuous factors and
medians for categoric factors).
RESULTS
The demographic and clinical characteristics of
the 7490 patients in the study population (Table II)
were generally similar to those of the overall PSOLAR
population (data not shown). The following
characteristics were enriched among patients who
developed symptoms suggestive of depression
compared with the study population: nonwhite
race, medical and psychiatric comorbidities, lower
Abbreviations used:
AE: adverse event
CI: confidence intervals
HADS-D: Hospital Anxiety and Depression Scalee
Depression
HR: hazard ratio
HRQoL: health-related quality of life
IR: incidence rate
MedDRA: Medical Dictionary for Regulatory
Activities
PGA: Physician’s Global Assessment
PSOLAR: Psoriasis Longitudinal Assessment and
Registry
PY: patient-year
TNFea: tumor necrosis factorea
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education level, and public insurance. Among
patients who reported an AE of depression, the
following characteristics were enriched: psychiatric
comorbidities (anxiety), lower education level, pri-
vate insurance, current/past smoking, and less se-
vere psoriasis as assessed by body surface area and
the Physician’s Global Assessment (PGA).
Incidence of depression
A total of 532 study patients developed symptoms
suggestive of depression (HADS-D score $8
[Table III]). The IR was lower for the biologics cohort
(IR, 3.01; 95% CI, 2.73-3.32) than for the
phototherapy cohort (IR, 5.85; 95% CI, 4.29-7.97)
and the conventional systemic cohort (IR, 5.70; 95%
CI, 4.58-7.10). The IRs for the individual biologic
therapy cohorts (ustekinumab, infliximab, etaner-
cept, and adalimumab) were similar to those for the
overall biologic cohort and lower than those for the
phototherapy and conventional systemic cohorts.
A total of 37 AEs of depression were reported in
the study population (Table IV). The IRs for the
biologic (IR, 0.21; 95% CI, 0.15-0.31), phototherapy
(IR, 0.55; 95% CI, 0.21-1.47), and conventional
systemic agent cohorts (IR, 0.14; 95% CI, 0.03-0.55)
were lower than those for depressive symptoms. The
IRs of AEs of depression were similar among groups;
however, the analysis was limited by the low
numbers of events and the wide CIs.
Factors predictive of symptoms suggestive of
depression
On the basis of the Cox model, treatment with
biologics reduced the risk for depressive symptoms
(HR, 0.76; 95% CI, 0.59e0.98) compared with
conventional systemic therapy, whereas photo-
therapy did not affect risk (HR, 1.05; 95% CI,
0.71-1.54]) (Table V). Among the individual
biologics, only adalimumab significantly lowered
the risk for depressive symptoms (HR, 0.63; 95%
CI, 0.46-0.86). Ustekinumab and infliximab did not
lower risk, but the upper limits of the CIs were only
slightly higher than 1.00 (HR, 0.80; 95% CI, 0.60e1.06
and HR, 0.70; 95% CI, 0.47-1.03, respectively).
Etanercept did not appear to lower risk (HR, 0.91;
95% CI, 0.67-1.23). Given that oral retinoids have
been associated with depressive symptoms and
depression,14 we conducted a sensitivity analysis
excluding patients with concomitant retinoid use
from all cohorts. The results of the primary analysis
were minimally affected. Although combined
biologics treatment was no longer associated with
reduced risk for depressive symptoms (HR, 0.77; 95%
CI, 0.58-1.00; P = .0542 [data not shown]), the point
estimate and CI were very similar to those in the
primary analysis (HR, 0.76 and 95% CI, 0.59-0.98,
respectively). Furthermore, the reduced risk for
depressive symptoms with adalimumab treatment
persisted (HR, 0.63; 95% CI, 0.46-0.87; P = .0053 [data
not shown]). Factors that increased risk for
depressive symptoms included increasing age,
nonwhite race, history of anxiety, psoriatic arthritis,
higher baseline PGA score, and chronic obstructive
pulmonary disease. Factors that decreased the risk
included the following: having a college/university
education; increasing years since psoriasis began;
having a decreased, stable, or 1-point or less increase
in PGA; and having private insurance. The low
numbers of events precluded Cox modeling of the
AEs of depression.
Suicidality
A total of 21 patients in the overall PSOLAR
population completed suicide, attempted suicide, or
experienced suicidal ideation (IR, 43.0 per 100,000
patient-years [PYs]) (Table VI). Of note, not all of
these patients met the inclusion criteria for the study
population in the analysis of IRs and HRs reported
earlier. Of these 21 patients, 3 completed suicide (IR,
6.1 per 100,000 PYs), 8 attempted suicide, and 10
experienced suicidal ideation (TableVI). All 3 patients
who completed suicide were male; 1 patient was
being treated with ustekinumab at the time of suicide
(within 91 days) and 1 each had been treated
previously with ustekinumab and adalimumab,
etanercept, or alefacept, respectively (see Table VI
for additional details). Of the 8 patients who
attempted suicide, 3 were receiving etanercept, 2
infliximab, and 1 adalimumab and 2 were not
receiving any systemic psoriatic treatment at the
time of the event. All but 1 of the patients who
attempted suicide had previously received biologics.
Of the 10 patients with suicidal ideation, 5
were receiving ustekinumab, 2 etanercept, and 1
adalimumab and 2 were not receiving any treatment
at the time of the event. All patients who experienced
suicidal ideation had previously received biologic
therapy.
DISCUSSION
Our study indicates that, compared with
conventional systemic therapy, biologic therapy is
associated with a decreased risk for development
of depressive symptoms among patients with
moderate-to-severe psoriasis. Of the biologics exam-
ined, adalimumab had the strongest association with
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Table I. Summary of the Hospital Anxiety and Depression Scale-Depression
A/D Question Range
A I feel tense or ‘‘wound up.’’ 0 = Not at all
1 = From time to time, occasionally
2 = A lot of the time
3 = Most of the time
D I still enjoy the things I used to enjoy. 0 = Definitely as much
1 = Not quite as much
2 = Only a little
3 = Hardly at all
A I get a sort of frightened feeling as if something
awful is about to happen.
0 = Not at all
1 = A little, but it doesn’t worry me
2 = Yes, but not too badly
3 = Very definitely and quite badly
D I can laugh and see the funny side of things. 0 = As much as I always could
1 = Not quite so much now
2 = Definitely not so much now
3 = Not at all
A Worrying thoughts go through my mind. 0 = Only occasionally
1 = From time to time, but not too often
2 = A lot of the time
3 = A great deal of the time
D I feel cheerful. 0 = Most of the time
1 = Sometimes
2 = Not often
3 = Not at all
A I can sit at ease and feel relaxed. 0 = Definitely
1 = Usually
2 = Not often
3 = Not at all
D I feel as if I am slowed down. 0 = Not at all
1 = Sometimes
2 = Very often
3 = Nearly all the time
A I get a sort of frightened feeling like ‘‘butterflies’’ in the stomach. 0 = Not at all
1 = Occasionally
2 = Quite often
3 = Very often
D I have lost interest in my appearance. 0 = I take just as much care as ever
1 = I may not take quite as much care
2 = I don’t take as much care as I should
3 = Definitely
A I feel restless as I have to be on the move. 0 = Not at all
1 = Not very much
2 = Quite a lot
3 = Very much indeed
D I look forward with enjoyment to things. 0 = As much as I ever did
1 = Rather less than I used to
2 = Definitely less than I used to
3 = Hardly at all
A I get sudden feelings of panic. 0 = Not at all
1 = Not very often
2 = Quite often
3 = Very often indeed
Continued
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lower risk, with the findings for ustekinumab and
infliximab trending toward lower risk but not
achieving statistical significance. We were unable to
assess risk for AEs of depression on account of the
low number of events.
In addition, socioeconomic factors appeared to be
important considerations. The modeled analysis
showed that having achieved a higher level of
education appears to reduce the risk for
development of depressive symptoms, as has been
demonstrated in other studies.15,16 Having private
insurance also decreased the risk for development of
depressive symptoms in our analysis.
Depressive symptoms were assessed by using the
HADS-D instrument (Table I). The sensitivity and
specificity of this instrument for capturing true
depression is estimated at around 0.8 when a cutoff
score of 8 or higher is used. However, the HADS-D
has not been validated in psoriasis, and it is
important to note that responses to some of the
questions may reflect aspects of psoriasis rather than
frank depression.
Given the relatively high incidence of depressive
symptoms (occurring in 532 patients), it is surprising
that relatively few patients reported an AE of
depression (37 events). There are several possible
explanations for this discrepancy, including
potential under-reporting or underdiagnosis of
depression, the impact of treatment on depression,
and elements of the study design. In particular,
patients were followed only until their first
occurrence of either depressive symptoms or AE of
depression. Some patients who developed
depressive symptoms may have progressed to also
have an AE of depression; however, the latter would
not have been captured in this analysis. In addition,
clinical depression may be underdiagnosed or
under-reported in a dermatology setting. PSOLAR
does not capture whether patients with elevated
HADS-D scores were specifically evaluated for
depression by a mental health specialist or primary
care provider. An earlier review noted that the
2-question Patient Health Questionnaire-2 (‘‘Over
the past 2 weeks, have you felt down, depressed, or
hopeless?’’ and ‘‘Over the past 2 weeks, have you felt
little interest or pleasure in doing things?’’) may be as
effective as more complex tools for depression
screening.17 A simple, practical approach for
depression screening may be more feasible than
use of the HADS-D instrument in an outpatient
dermatology setting and may promote appropriate
referrals for patients at risk.
Despite possible confounding factors or study
design, it is possible that biologic therapy reduces
the risk for frank depression in patients with
psoriasis. We were unable to model this risk on
account of the low numbers of AEs of depression.
Two potential reasons could explain why biologics
may reduce these risks. First, dysregulated systemic
inflammation may promote depression.18 Cytokines
can access the central nervous system and elevated
tumor necrosis factor-a (TNF-a) levels have been
detected in the serum of patients with depression.19
Consequently, neutralization of inflammatory
mediators that are common to psoriasis and
depression could alleviate depressive symptoms
and prevent progression to depression. Second,
various psychosocial factors associated with
psoriasis may promote depression. For example,
the visibility of psoriasis lesions may lead to social
stigmatization.20 Furthermore, the overall impact of
psoriasis on health-related quality of life (HRQoL)
has been shown to be similar to that of other
major chronic illnesses.21 Thus, improvement in
psoriasis may be expected to enhance social
functioning and HRQoL, which may in turn reduce
risk for development of depressive symptoms and
depression.
Our data are in line with the data from pivotal
clinical trials for etanercept, adalimumab, infliximab,
and ustekinumab, which show improvement of
depressive symptoms with treatment. Both
depressive symptoms and HRQoL measures
improved in parallel with Psoriasis Area and
Severity Index responses.7-10 Major strengths of our
analysis, as compared with analyses of tertiary study
Table I. Cont’d
A/D Question Range
D I can enjoy a good book or radio or TV program. 0 = Often
1 = Sometimes
2 = Not often
3 = Very seldom
Patients were asked to complete the HADS questionnaire on the basis of their feelings experienced in the past week. Anxiety and depression
were assessed on the basis of the total score, a summation of the individual scores (HADS-D questions marked by a D). Scores of 8 or higher
for the HADS-D scale were considered elevated.
A, Anxiety; D, depression; HADS-D, Hospital Anxiety and Depression ScaleeDepression; TV, television.
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Table II. Demographic and clinical characteristics of the study population
Characteristic
Developed symptoms suggestive of depression* Reported AE of depressiony
TotalNo Yes No Yes
(n = 6958) (n = 532) (n = 7453) (n = 37) (n = 7490)
Age, years, mean 6 SD 47.8 6 13.8 51.0 6 13.5 48.0 6 13.8 46.4 6 13.4 48.0 6 13.8
Sex, female 2792 (40.1) 214 (40.2) 2985 (40.1) 21 (56.8) 3006 (40.1)
Race
White 5812 (83.5) 407 (76.5) 6186 (83.0) 33 (89.2) 6219 (83.0)
Black 256 (3.7) 23 (4.3) 277 (3.7) 2 (5.4) 279 (3.7)
Asian 272 (3.9) 45 (8.5) 317 (4.3) - 317 (4.2)
Hispanic 437 (6.3) 42 (7.9) 479 (6.4) - 479 (6.4)
Other 180 (2.6) 15 (2.8) 193 (2.6) 2 (5.4) 195 (2.6)
BMI, mean 6 SD 30.5 6 6.8 30.7 6 7.3 30.5 6 6.8 32.2 6 9.1 30.5 6 6.9
Duration of PsO, mean 6 SD 17.9 6 13.1 17.5 6 13.2 17.8 6 13.1 19.3 6 12.7 17.8 6 13.1
PGA score, mean 6 SD 1.9 6 1.2 1.9 6 1.2 1.9 6 1.2 1.4 6 1.3 1.9 6 1.2
PGA score distribution
0 = clear 933 (13.6) 76 (14.4) 998 (13.6) 11 (29.7) 1009 (13.7)
1 = minimal 1750 (25.5) 126 (23.9) 1864 (25.4) 12 (32.4) 1876 (25.4)
2 = mild 1927 (28.1) 131 (24.8) 2053 (28.0) 5 (13.5) 2058 (27.9)
3 = moderate 1721 (25.1) 147 (27.8) 1862 (25.4) 6 (16.2) 1868 (25.3)
4 = marked 443 (6.5) 42 (8.0) 482 (6.6) 3 (8.1) 485 (6.6)
5 = severe 80 (1.2) 6 (1.1) 86 (1.2) d 86 (1.2)
% BSA, mean 6 SD 10.6 6 16.0 14.0 6 19.7 10.9 6 16.3 6.0 6 12.3 10.8 6 16.3
PsA, yes 2292 (33.0) 226 (42.5) 2504 (33.7) 14 (37.8) 2518 (33.7)
PsA, confirmed yes 865 (12.5) 99 (18.6) 960 (12.9) 4 (10.8) 964 (12.9)
CAD/MI/ACVD/stroke/TIA, yes 415 (6.0) 40 (7.5) 454 (6.1) 1 (2.7) 455 (6.1)
Cardiovascular disease
Atherosclerotic disease 237 (3.4) 26 (4.9) 262 (3.5) 1 (2.7) 263 (3.5)
Coronary artery disease 207 (3.0) 20 (3.8) 227 (3.1) d 227 (3.0)
Myocardial infarction 155 (2.2) 14 (2.6) 169 (2.3) d 169 (2.3)
TIA/CVA/stroke 69 (1.0) 9 (1.7) 78 (1.1) d 78 (1.0)
Pulmonary disease
Obstructive pulmonary 82 (1.2) 13 (2.4) 94 (1.3) 1 (2.7) 95 (1.3)
Diabetes, type I or II 755 (10.9) 81 (15.2) 833 (11.2) 3 (8.1) 836 (11.2)
Cancer, other/skin melanomaz 259 (3.7) 26 (4.9) 285 (3.8) d 285 (3.8)
Psychiatric illness
Anxiety 391 (5.6) 43 (8.1) 430 (5.8) 4 (10.8) 434 (5.8)
Bipolar 42 (0.6) 8 (1.5) 50 (0.7) d 50 (0.7)
Schizophrenia 10 (0.1) 2 (0.4) 12 (0.2) d 12 (0.2)
Suicidal ideation 2 (0.0) 1 (0.2) 3 (0.0) d 3 (0.0)
Prior treatments
Phototherapy 3931 (56.5) 283 (53.2) 4192 (56.3) 22 (59.5) 4214 (56.3)
Immunomodulatorsx 3285 (47.2) 259 (48.7) 3526 (47.3) 18 (48.7) 3544 (47.3)
Biologics
Adalimumab 2148 (30.9) 159 (29.9) 2294 (30.8) 13 (35.1) 2307 (30.8)
Etanercept 2958 (42.5) 224 (42.1) 3167 (42.5) 15 (40.5) 3182 (42.5)
Infliximab 1076 (15.5) 95 (17.9) 1167 (15.7) 4 (10.8) 1171 (15.6)
Ustekinumab 1490 (21.4) 122 (22.9) 1598 (21.4) 14 (37.8) 1612 (21.5)
Insurance
None 465 (6.7) 49 (9.2) 512 (6.9) 2 (5.4) 514 (6.9)
Public 1085 (15.6) 148 (27.8) 1223 (16.4) 10 (27.0) 1233 (16.5)
Private 5001 (72.0) 291 (54.7) 5269 (70.8) 23 (62.2) 5292 (70.8)
Both public/private 397 (5.7) 44 (8.3) 439 (5.9) 2 (5.4) 441 (5.9)
Continued
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populations and clinical trials, include longer
duration of follow-up, a representative study
population, and an observational real-world setting
design. Weaknesses include the following: the
inherent limitations of the HADS-D instrument, as
noted earlier; patient self-reporting of AEs of
depression; possible inadequate capture of
depressive events; and lack of data regarding alcohol
consumption and other medications (such as
antidepressants). Of note, although oral retinoids
have been associated with depression, the results of
a sensitivity analysis provided evidence against
confounding by retinoid use. In addition, there are
biases inherent to the longitudinal cohort design,
such as the inability to account for all baseline
differences between cohorts that might affect
outcome. Lastly, smaller sample sizes may limit the
ability to interpret some analyses, (eg, the post hoc
analysis excluding patients with concomitant
retinoid use).
We also presented a descriptive analysis of
suicidality among patients enrolled in PSOLAR.
Overall, the IR of suicidal ideation, attempted
suicide, or completed suicide was low (43.0 per
100,000 PYs). Although it is difficult to directly
compare this rate with other published data, the
Table IV. Incidence (events per 100 PYs) of adverse
events of depression reported during monotherapy
in patients with no symptoms suggestive of
depression (HADS-D score\8) or self-reported
history of depression at enrollment in PSOLAR
Therapy
No. of
cases
Total
PYs
Incidence rate
(95% CI)
Biologic agents 31 14427 0.21 (0.15-0.31)
Ustekinumab 13 6054 0.21 (0.12-0.37)
Infliximab 2 1554 0.13 (0.03-0.51)
Etanercept 5 2968 0.17 (0.07-0.40)
Adalimumab 11 3850 0.29 (0.16-0.52)
Phototherapy 4 727 0.55 (0.21-1.47)
Conventional systemics 2 1452 0.14 (0.03-0.55)
The overall total of PYs for biologic agents has been rounded to
the nearest whole number.
CI, Confidence interval; HADS-D, Hospital Anxiety and Depression
ScaleeDepression; PSOLAR, Psoriasis Longitudinal Assessment and
Registry; PY, patient-year.
Table II. Cont’d
Characteristic
Developed symptoms suggestive of depression* Reported AE of depressiony
TotalNo Yes No Yes
(n = 6958) (n = 532) (n = 7453) (n = 37) (n = 7490)
Education
Less than high school 383 (5.6) 59 (11.2) 438 (5.9) 4 (10.8) 442 (6.0)
High school 2108 (30.5) 189 (35.9) 2283 (30.9) 14 (37.8) 2297 (30.9)
College/university 3613 (52.3) 224 (42.5) 3820 (51.7) 17 (46.0) 3837 (51.6)
Graduate/professional 800 (11.6) 55 (10.4) 853 (11.5) 2 (5.4) 855 (11.5)
Smoking, current/past 3755 (54.0) 315 (59.2) 4044 (54.3) 26 (70.3) 4070 (54.4)
Data are presented as number (%), unless otherwise specified.
AE, Adverse event; ACVD, atherosclerotic cardiovascular disease; BMI, body mass index; BSA, body surface area; CAD, coronary artery disease;
CVA, cerebrovascular accident; MI, myocardial infarction; n, number of patients; PGA, Physician’s Global Assessment; PsA, psoriatic arthritis;
PsO, psoriasis; SD, standard deviation; TIA, transient ischemic attack.
*Symptoms suggestive of depression were defined as a score of 8 or higher on the Hospital Anxiety and Depression ScaleeDepression
questionnaire.
yAEs of depression were collected using Standardized Medical Dictionary for Regulatory Activities Queries for Depression and Suicide/Self-injury.
zOther/skin melanoma was defined as patients with basal cell carcinoma, squamous cell carcinoma, melanoma, unknown skin cancer, or other
cancer.
xImmunomodulators included cyclosporine, methotrexate, mycophenolate mofetil, oral tacrolimus, and other.
Table III. Incidence (events per 100 PYs) of
symptoms suggestive of depression (HADS-D score
$8) by monotherapy in patients with no symptoms
suggestive of depression (HADS-D score\8) or
self-reported history of depression at enrollment in
PSOLAR
Therapy
No. of
cases
Total
PYs
Incidence rate
(95% CI)
Biologic agents 412 13681 3.01 (2.73-3.32)
Ustekinumab 173 5739 3.01 (2.60-3.50)
Infliximab 44 1461 3.01 (2.24-4.05)
Etanercept 98 2776 3.53 (2.90-4.30)
Adalimumab 97 3705 2.62 (2.15-3.19)
Phototherapy 40 684 5.85 (4.29-7.97)
Conventional systemics 80 1403 5.70 (4.58-7.10)
CI, Confidence interval; HADS-D, Hospital Anxiety and Depression
ScaleeDepression; PSOLAR, Psoriasis Longitudinal Assessment and
Registry; PY, patient-year.
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suicide rate among patients with psoriasis in the
General Practice Research Database was 90 per
100,000 PYs.3
Although biologic therapies have been associated
with a low risk for suicidality,22 an imbalance in
suicide and suicidal ideation has been previously
observed among patients treated with an interleukin
17 receptor inhibitor.23 It is important to note that
causality remains uncertain22 and differences in
study design could be contributing to the perceived
imbalance. Our studies do not assess interleukin 17
inhibitors, and more data from other registries that
capture the use of this class of drug are needed to
understand this potential risk. With consideration of
the role of TNFea in depression, further study may
be beneficial to determine whether biologic
therapies targeting other cytokines may have a
different impact on depression and suicide relative
to antieTNFea agents.19
Overall, this study contributes to the body of
literature suggesting that treatment with biologic
agents may reduce the risk for development of
depressive symptoms among patients with
moderate-to-severe psoriasis. It also provides a
longitudinal description of depressive symptoms,
depression events, and suicidality in a large cohort
of patients with psoriasis. Further studies are needed
to fully understand how biologics, including novel
agents, affect the risk for depression and suicide
among patients with psoriasis.
Table V. Multivariate Cox model for symptoms suggestive of depression
Covariate* Hazard Ratio (95% CI) P value
Exposure
Biologic agents vs conventional systemic agents 0.76 (0.59-0.98) .0367
Ustekinumab vs conventional systemic agents 0.80 (0.60-1.06) .1208
Infliximab vs conventional systemic agents 0.70 (0.47-1.03) .0699
Etanercept vs conventional systemic agents 0.91 (0.67-1.23) .5220
Adalimumab vs conventional systemic agents 0.63 (0.46-0.86) .0034
Phototherapy vs conventional systemic agents 1.05 (0.71-1.54) .8159
Age/10 y 1.12 (1.05-1.21) .0015
Sex: male vs female 1.09 (0.91-1.30) .3644
Race: nonwhite vs white 1.72 (1.39-2.13) <.0001
Years since psoriasis 0.99 (0.98-1.00) .0026
Baseline PGA
2-3 1.45 (1.17-1.79) .0005
4-5 2.36 (1.62-3.43) <.0001
Change in PGA (HADS-D score)
2 or lower 0.44 (0.33-0.59) <.0001
1 0.66 (0.52-0.84) .0006
1 0.69 (0.52-0.91) .0101
$2 1.01 (0.70-1.44) .9734
Psoriatic arthritis: yes vs no 1.58 (1.32-1.88) <.0001
Diabetes: yes vs no 1.15 (0.90-1.48) .2685
Schizophrenia: yes vs no 2.16 (0.53-8.79) .2818
Anxiety: yes vs no 1.64 (1.19-2.25) .0024
Bipolar disease: yes vs no 2.01 (0.99-4.09) .0547
Chronic obstructive pulmonary disease: yes vs no 2.10 (1.19-3.71) .0105
CAD/MI/ACVD/stroke/TIA: yes vs no 0.81 (0.57-1.15) .2440
Insurance
Public vs none 1.29 (0.92-1.81) .1455
Private vs none 0.62 (0.45-0.85) .0029
Both public and private vs none 0.94 (0.60-1.46) .7806
Education: $college/university vs\high school 0.79 (0.66-0.95) .0114
Boldface indicates statistical significance.
ACVD, Atherosclerotic cardiovascular disease; CAD, coronary artery disease; CI, confidence interval; HADS-D, Hospital Anxiety and Depression
ScaleeDepression; MI, myocardial infarction; PGA, Physician’s Global Assessment; TIA, transient ischemic attack.
*Potential covariates included age, sex, ethnicity, educational status, psychiatric history, type of insurance, body mass index, duration of
psoriasis, historic peak PGA, baseline PGA, change in disease severity (defined as change in PGA from peak or baseline to time of event or
last available PGA score), comorbidities (including psoriatic arthritis, diabetes, chronic obstructive pulmonary disease, and cardiovascular
disease [defined as CAD, MI, ACVD, stroke, and TIA]), and smoking status. All covariates with an overall univariate P value less than .2 were
included in the Cox model.
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